Helmholtz Gemeinschaft


Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
[img] MS Word (Supplementary Information)

Item Type:Article
Title:Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Creators Name:Gampenrieder, S.P. and Rinnerthaler, G. and Tinchon, C. and Petzer, A. and Balic, M. and Heibl, S. and Schmitt, C. and Zabernigg, A.F. and Egle, D. and Sandholzer, M. and Singer, C.F. and Roitner, F. and Hager, C. and Andel, J. and Hubalek, M. and Knauer, M. and Greil, R.
Abstract:BACKGROUND: About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a promising new target for antibody-drug conjugates (ADCs) currently under investigation. Until now, little is known about the frequency and the prognostic value of low HER2-expression in metastatic breast cancer (MBC). PATIENTS AND METHODS: The MBC-Registry of the Austrian Study Group of Medical Tumor Therapy (AGMT) is a multicenter nationwide ongoing registry for MBC patients in Austria. Unadjusted, univariate survival probabilities of progression-free survival (PFS) and overall survival (OS) were calculated by the Kaplan-Meier method and compared by the log-rank test. Multivariable adjusted hazard ratios were estimated by Cox regression models. In this analysis, only patients with known HER2 status and available survival data were included. RESULTS: As of 11/15/2020, 1,973 patients were included in the AGMT-MBC-Registry. Out of 1,729 evaluable patients, 351 (20.3%) were HER2-positive, 608 (35.2%) were HER2-low and 770 (44.5%) were completely HER2-negative (HER2-0). Low HER2-expression was markedly more frequent in the hormone-receptor(HR)+ subgroup compared to the triple-negative subgroup (40% vs. 23%). In multivariable analysis, low HER2 expression did not significantly influence OS neither in the HR+ (HR 0.89; 95% CI 0.74-1.05; P = 0.171) nor in the triple-negative subgroup (HR 0.92; 95% CI 0.68-1.25; P = 0.585), when compared to completely HER2-negative disease. Similar results were observed when HER2 IHC 2+ patients were compared to IHC 1+ or 0 patients. CONCLUSION: Low-HER2 expression did not have any impact on prognosis of metastatic breast cancer in this real-world population.
Keywords:Metastatic Breast Cancer, HER2-Low, HER2-Positive, HER2-Negative, OS, PFS, Registry, Real-World Data
Source:Breast Cancer Research
Publisher:BioMed Central
Page Range:112
Date:14 December 2021
Official Publication:https://doi.org/10.1186/s13058-021-01492-x
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library